Status:

COMPLETED

Woebot for Substance Use Disorders

Lead Sponsor:

Woebot Health

Collaborating Sponsors:

Stanford University

Conditions:

Substance Use Disorders

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

Brief Summary

Phase 1 of this study aims to develop a digitally-delivered substance use disorder program through the Woebot app-based platform (W-SUDs) and evaluate the effectiveness of, patient satisfaction with a...

Eligibility Criteria

Inclusion

  • All genders
  • 18-65 years
  • Must have access to a smartphone and able to download the W-SUDs app
  • Committed to engage with app and complete assessments
  • Be willing to provide email address (to distribute incentives)
  • Be literate in English (as W-SUDs conversational and video materials will be in English)
  • Endorse a substance use concern according to the DAST-10 and/or AUDIT-C scale cutoffs for problematic use

Exclusion

  • Pregnancy (as W-SUDs will not be specifically developed to address the unique needs of this population)
  • Suicide attempt or within the past year
  • Drug or alcohol overdose within the past year

Key Trial Info

Start Date :

March 26 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 31 2020

Estimated Enrollment :

101 Patients enrolled

Trial Details

Trial ID

NCT04096001

Start Date

March 26 2020

End Date

August 31 2020

Last Update

August 31 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Woebot Labs Inc

San Francisco, California, United States, 94107